ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting

    Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry

    Denis Choquette1, J. Carter Thorne2, John T. Kelsall3, Michel Zummer4, Michael Starr5, Maqbool K. Sheriff6, William G. Bensen7, Andrew Chow8, Philip Baer9, Emmanouil Rampakakis10, John S. Sampalis10, Francois Nantel11, Allen J. Lehman12, Susan M. Otawa12 and May Shawi13, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 4Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 5Montreal General Hospital, Montreal, QC, Canada, 6Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 7Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 8University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 9Private Practice, Scarborough, ON, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada, 13Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
  • Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting

    Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort

    James Bluett1, Catharine Morgan1, Layla Thurston2, Darren Plant1, Ann W. Morgan3, Anthony G. Wilson4, John Isaacs5, Kimme L. Hyrich1, Lis Cordingley1 and Anne Barton1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2Manchester Medical School, The University of Manchester, Manchester, United Kingdom, 3NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 5National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom

    Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
  • Abstract Number: 2811 • 2013 ACR/ARHP Annual Meeting

    Disease Characteristics and Treatment Patterns In US Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection

    Ruchika Patel1 and Joshua Baker2, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C (HCV) is estimated at 0.02%, affecting around 40,000 Americans. To our knowledge, no existing…
  • Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting

    Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice

    Jos Hendrikx1, Jaap Fransen2, Alessandro Toniolo3 and Piet L.C.M. van Riel4, 1Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Pfizer Pharmaceuticals, Rome, Italy, 4Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist,  though an evidence base for their use in monitoring…
  • Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting

    A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis

    Monica Luchi, Rosanne Fidelus-Gort, Diane Douglas, Haifeng Zhang, Robert Flores, Robert Newton, Peggy Scherle, Swamy Yeleswaram, Xuejun Chen and Victor Sandor, Incyte Corporation, Wilmington, DE

    Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…
  • Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting

    Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial

    P.H.P. de Jong1, A.E.a.M. Weel2, J.J. Luime3, P.J. Barendregt2, A.H. Gerards4, P.A. van der Lubbe4, M.H. de Jager5, P.B. de Sonnaville6, D. van Zeben7, B.A. Grillet8 and J.M.W. Hazes3, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 4Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 5Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 6Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 7Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 8Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and  maintained with less treatment…
  • Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting

    Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice

    Gabriela Ávila1, Sara Marsal1, Arnald Alonso1, Carolina Diaz2, Estefanía Quesada-Masachs2, María López-Lasanta1 and Isabel Acosta3, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, 3Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
  • Abstract Number: 1484 • 2013 ACR/ARHP Annual Meeting

    Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis

    Catherine Sullivan1, Gadintshware Gaoatswe2, James Gibney3, Marie Louise Healy4, Michele Doran5, David Kane1, Donal O'Shea2 and Ronan Mullan1, 1Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, 2Obesity Immunology Group, Education and Research Centre, St Vincent's University Hospital, UCD, Dublin 4, Ireland, 3Department of Endocrinology, Tallaght Hospital, TCD, Dublin 24, Ireland, 4Department of Endocrinology, St James Hospital, TCD, Dublin 8, Ireland, 5Rheumatology Dept, St James's Hospital, Dublin, Ireland

    Background/Purpose: Glucagon-like peptide-1 (GLP-1) analogues such as liraglutide, which are used for the treatment of type 2 diabetes (T2DM), mimic the action of endogenous incretin…
  • Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting

    10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes

    I.M. Markusse1, G. Akdemir1, M. van den Broek1, L. Dirven1, R.J. Goekoop2, K.H. Han3, M. van Oosterhout4, P.J.S.M. Kerstens5, W.F. Lems6, T.W.J. Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Haga Hospital, The Hague, Netherlands, 3Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 4Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 5Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 6Rheumatology, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…
  • Abstract Number: 1475 • 2013 ACR/ARHP Annual Meeting

    Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis

    Glen S. Hazlewood1, J. Carter Thorne2, Janet E. Pope3, Juan Xiong4, Gilles Boire5, Boulos Haraoui6, Carol A. Hitchon7, Edward C. Keystone8, Diane Tin9 and Vivian P. Bykerk10, 1Medicine, University of Calgary, Calgary, AB, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3St Joseph Health Care, London, ON, Canada, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 6Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 7Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 8Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 9The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 10Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: To determine the comparative survival of initial treatment with subcutaneous (sc) methotrexate (MTX) versus oral MTX for patients with early rheumatoid arthritis (ERA) in…
  • Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting

    The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate

    T.W.J. Huizinga1, Fiona Brock2, Urs Kerkmann3 and Gaia Gallo3, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Quanticate, Hitchin, Hertfordshire, United Kingdom, 3Pfizer Europe, Rome, Italy

    Background/Purpose:  Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…
  • Abstract Number: 1327 • 2012 ACR/ARHP Annual Meeting

    Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea

    Mi-Il Kang, Yoon Kang, Hee-Jin Park, Hyang-Sun Lee, Sang-Won Lee, Yong-Beom Park and Soo-Kon Lee, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose:  The previous studies reported that intensive treatment-strategies, including biological agents and glucocorticoids, can improve the severity of early rheumatoid arthritis. However, there was no…
  • Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting

    Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment

    Steven De Bruyn1, Béla Gachályi2, Bernadette Rojkovich3, Slavomir Bruk4, Petr Sramek5, Mariusz Korkosz6, Krzysztof Krause7, Pieter Schoen8, Laura Sargentini-Maier9, Joke D'Artois10, Katrien Verschueren10, Katelijne De Swert10, Gerhard Arold11 and Josefin-Beate Holz12, 1Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, 2Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, 3II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, 4Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, 5Pharmaceutical Research Associates CZ, Praha, Czech Republic, 6Malopolskie Centrum Medyczne, Krakow, Poland, 7Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, 8Project Management, Ablynx N.V., Zwijnaarde, Belgium, 9Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 10Clinical Development, Ablynx nv, Zwijnaarde, Belgium, 11Medical Affairs, PRA International GmbH, Berlin, Germany, 12Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
  • Abstract Number: 983 • 2012 ACR/ARHP Annual Meeting

    Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 As a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis

    Jing Cui1 and International RA Consortium on Therapy (InteRACT)2, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy and Division of Genetics, Boston, MA

    Background/Purpose:  There are no biomarkers that predict response to anti-TNF therapy in rheumatoid arthritis (RA).  Here, we conduct a genome-wide association study (GWAS) to identify…
  • Abstract Number: 833 • 2012 ACR/ARHP Annual Meeting

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy

    Edward Bernton1, Eduard Krantz2 and William Gannon Jr.3, 1Protalex Inc., Summit, NJ, 2Parexel Clinical Pharmacology, Bloemfontein, South Africa, 3Capital City Technical Consulting, Inc., Washington, DC

    Background/Purpose: PRTX-100 is highly-purified GMP staphylococcal protein A (SpA) that binds with extremely high affinity to the Vh antibody framework region of Clade Vh3 immunoglobulins. …
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology